Cite
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.
MLA
Bellon, Jennifer R., et al. “Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.” International Journal of Radiation Oncology, Biology, Physics, vol. 113, no. 1, May 2022, pp. 117–24. EBSCOhost, https://doi.org/10.1016/j.ijrobp.2021.12.173.
APA
Bellon, J. R., Tayob, N., Yang, D. D., Tralins, J., Dang, C. T., Isakoff, S. J., DeMeo, M., Burstein, H. J., Partridge, A. H., Winer, E. P., Krop, I. E., & Tolaney, S. M. (2022). Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. International Journal of Radiation Oncology, Biology, Physics, 113(1), 117–124. https://doi.org/10.1016/j.ijrobp.2021.12.173
Chicago
Bellon, Jennifer R., Nabihah Tayob, David D. Yang, Jordan Tralins, Chau T. Dang, Steven J. Isakoff, Michelle DeMeo, et al. 2022. “Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.” International Journal of Radiation Oncology, Biology, Physics 113 (1): 117–24. doi:10.1016/j.ijrobp.2021.12.173.